The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Will this trial change my practice? | Proceedings of EuroPCR

Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus drug-eluting stent in coronary disease)

EuroIntervention 2015;11:366-368. DOI: 10.4244/EIJV11I3A72

1. The Heart Hospital, University College London Hospitals UCLH, London, United Kingdom; 2. Deutsches Herzzentrum München, Technische Universität München and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Ger
The “Will this trial change my practice?” sessions at PCR

The aim of the article is to capture the session at EuroPCR 2015, communicate the analysis of the trialists, and report the views expressed in the interactive discussion.

Introduction to the session

Bioresorbable stents (BRS) have been described as the fourth revolution in interventional cardiology. ABSORB II is the first randomised controlled clinical trial (RCT) comparing an everolimus-eluting BRS with a second-generation everolimus-eluting permanent metallic stent (DES)1. A dedicated interactive EuroPCR session subjected this study to focused scrutiny with the help of facilitators consisting of Ibrahim Al-Rashdan, Robert ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients